SafeHeal® Closes Oversubscribed €35 Million Series C Equity Financing
NEW YORK, NY, UNITED STATES, May 6, 2025 / EINPresswire.com / -- Financing led by Solar Eclipse with new investors Gideon Strategic Partners and M&L Healthcare, part of M&L Group, and returning investors Sofinnova Partners and one of the largest Multinational life sciences corporations from a strategic standpoint.
Proceeds will support the completion of SafeHeal's IDE pivotal study and preparation for commercial launch of their lead technology , Colovac®.
SafeHeal®, a leading innovator in the field of colorectal cancer surgery, today announced a successful completion of an oversubscribed €35 million Series C equity financing to validate the use of Colovac®, a groundbreaking temporary endoluminal fecal bypass system. Colovac is intended as an alternative to temporary diverting ostomy for patients undergoing colorectal cancer resection.
The proceeds leave SafeHeal well-funded to complete its IDE Pivotal study and accelerate preparation for commercial launch of their lead technology, Colovac.
In conjunction with the financing, Martin Sands and Steven Sands of Solar Eclipse will join as board member and observer respectively.
The Colovac endoluminal bypass system is a less-invasive alternative to temporary diverting ostomy, the current standard of care for patients undergoing colorectal resection. Diverting ostomy is applied prophylactically to most patients today undergoing a low anterior resection (LAR) and anastomosis. The ostomy temporarily diverts the stool away from the healing anastomosis to the outside of the body and into an ostomy bag. In most cases, the ostomy is needed only until the anastomosis has healed, and then it can be reversed, typically after 2-6 months. The eventual reversal of the ostomy requires another operation, with a second hospital stay, recovery period and associated complications. In some cases, the ostomy may not be reversed and becomes permanent. In addition to the potential surgical complications associated with ostomy procedures, patients may experience an impact to their quality of life due to social isolation, reduced physical activity and/or intimacy.
Colovac is an alternative to diverting ostomy, designed to eliminate the need for a temporary stoma in most patients. It aims to improve patient recovery and quality of life by eliminating stoma related complications including permanent stoma and eliminating the physical and emotional burden associated with stoma management and care.
Colovac has been successfully studied in over 100 patients in the U.S., Europe, and Asia and has received FDA Breakthrough Designation status.
'This is a very exciting time at SafeHeal as we continue to achieve a number of critical value-creating milestones in the coming months,' said Chris Richardson, President and Chief Executive Officer. 'We are grateful for the continuing support from Sofinnova Partners and delighted to welcome Solar Eclipse, Gideon and M&L Healthcare, part of M&L Group as new investors. This capital raise places SafeHeal in an excellent position to continue our momentum toward FDA approval and commercialization of Colovac.'
Chris Richardson, President & CEO, SafeHeal
'The current standard of care for treatment of Colon Resection is associated with significant morbidity, risk of permanent stoma and reduced quality of life, driving both the clinical community and regulators to search for better treatment options. SafeHeal is addressing this significant unmet medical need with a highly novel approach,' said Martin Sands of Solar Eclipse. 'I believe SafeHeal's therapeutic platform will dramatically improve quality of life and outcomes for patients with Colon Resections. I look forward to supporting the team to achieve multiple key milestones over the next 18 months.'
'We've been with SafeHeal since day one, when it was born out of our Medtech accelerator, MDStart. Our continued support in this Series C reflects a deep growing belief in their potential to revolutionize care for patients facing ostomy,' said Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners.
ABOUT SAFEHEAL®
SafeHeal SAS, headquartered in Paris, France, and its wholly owned U.S. subsidiary, SafeHeal Inc., is a clinical-stage medical device company developing Colovac, a device intended as an alternative to diverting ostomy in patients undergoing colorectal surgery. Colovac is a flexible endoluminal bypass sheath designed to reduce the contact of fecal content at the anastomotic site following colorectal surgery. The device is placed endoluminally and is fully reversible. The device remains in place for 7-10 days, until the body's natural healing and tissue repair processes are complete, after which it is removed during an endoscopic procedure without the need for a second surgical intervention. This enables patients to resume their normal life without the stigma and complications associated with an ostomy procedure. Colovac is an investigational device, not currently available for sale. For more information, please visit www.safeheal.com
MEDIA CONTACTS
USA
Scott DePierro
Vice President U.S. Operations
and Global Business Development, SafeHeal
203-444-0279
[email protected]
www.safeheal.com
Europe:
Karl-Heinz Blohm
Vice President, International, SafeHeal
+33 (0) 6 5181 7895
[email protected]
www.safeheal.com
###
Scott DePierro, VP US Operations & Global Business Dev
SafeHeal
+1 203-444-0279
email us here
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
an hour ago
- Health Line
Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.
Health Line
5 hours ago
- Health Line
Types of Schizophrenia
Key takeaways The DSM-5 no longer recognizes schizophrenia subtypes as separate diagnostic categories. However, the five classical subtypes (paranoid, hebephrenic, undifferentiated, residual, and catatonic) can still be helpful as specifiers for treatment planning. Schizophrenia affects approximately 1% of people in the United States, with men typically receiving a diagnosis in their late teens to early 20s and women typically receiving a diagnosis in their late 20s to early 30s. When schizophrenia occurs in children (which is rare), symptoms in older children and teens can include social withdrawal, sleep disruptions, impaired school performance, irritability, irregular behavior, and substance use. Schizophrenia is a chronic mental health disorder that affects: emotions the ability to think rationally and clearly the ability to interact with and relate to others The National Alliance on Mental Illness (NAMI) reports that research indicates that schizophrenia affects close to 1% of people in the United States. Men typically receive a schizophrenia diagnosis in their late teens to early 20s. Women typically receive a diagnosis in their late 20s to early 30s. Episodes of the illness can come and go, similar to the process of remission. When there's an 'active' period, an individual might experience: Current DSM-5 status Diagnostic changes were made for several disorders in the new Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, text revision (DSM-5-TR), including schizophrenia. In the past, an individual only had to have one of the symptoms to receive a confirmed diagnosis Now, a person must have at least two of the symptoms. The DSM-5 also removed the subtypes as separate diagnostic categories, based on the presenting symptom. This was found to not be helpful, since many subtypes overlapped with one another and were thought to decrease the diagnostic validity, according to the American Psychiatric Association (APA). Instead, these subtypes are now specifiers for the overarching diagnosis, to provide more detail for the clinician. Subtypes of schizophrenia Although the subtypes don't exist as separate clinical disorders anymore, they can still be helpful as specifiers and for treatment planning. There are five classical subtypes: paranoid hebephrenic undifferentiated residual catatonic Paranoid schizophrenia In 2013, the APA determined that paranoia was a positive symptom of the disorder. Paranoid schizophrenia was no longer considered a separate condition. However, the subtype description is still used because of how common this symptom is. Symptoms include: delusions hallucinations disorganized speech (word salad, echolalia) trouble concentrating behavioral impairment (impulse control challenges, emotional lability) flat affect Hebephrenic (disorganized) schizophrenia Hebephrenic or disorganized schizophrenia is still recognized by the International Statistical Classification of Diseases and Related Health Problems (ICD-10), although it's been removed from the DSM-5-TR. In this variation of schizophrenia, the individual does not have hallucinations or delusions. Instead, they experience disorganized behavior and speech. This can include: flat affect (inability to display emotions) speech disturbances disorganized thinking involuntary or unexpected emotions or facial reactions trouble with daily activities Undifferentiated schizophrenia Undifferentiated schizophrenia was the term used to describe when an individual displayed behaviors that were applicable to more than one type of schizophrenia. For instance, an individual who had catatonic behavior but also had delusions or hallucinations and disorganized speech might have received a diagnosis of undifferentiated schizophrenia. With the new diagnostic criteria, this merely signifies to the clinician that a variety of symptoms are present. Residual schizophrenia This 'subtype' is a bit tricky. It's been used when a person has a previous diagnosis of schizophrenia but no longer has any prominent symptoms of the disorder. The symptoms have generally lessened in intensity. Residual schizophrenia usually includes more 'negative' than positive symptoms, such as: flattened affect psychomotor difficulties slowed speech limited attentiveness to personal hygiene Many people with schizophrenia go through periods where their symptoms wax and wane (increase and decrease) and vary in frequency and intensity. Therefore, this designation is rarely used anymore. Catatonic schizophrenia Although catatonic schizophrenia had been listed as a subtype in the first Diagnostic and Statistical Manual of Mental Disorders first edition (1952) through the DSM-4 (1994), the DSM-5 removed it as a subtype. Catatonia is now considered a specifier. This is because it occurs in a variety of psychiatric and general medical conditions. Catatonic schizophrenia typically presents itself as immobility, but it can also look like: mimicking behavior mutism (inability to speak) a stupor-like condition (reduced responsiveness) Childhood schizophrenia Childhood schizophrenia isn't a subtype but rather an indicator of the time of diagnosis. A diagnosis in children is fairly uncommon. When it does occur, it can be severe. Early onset schizophrenia typically occurs between ages 13 and 18 years. A diagnosis under age 13 years is considered very early onset and is extremely rare. Symptoms in very young children are similar to those of developmental disorders, such as autism and attention deficit hyperactivity disorder (ADHD). These symptoms can include: language delays late or unusual crawling or walking irregular motor movements It's important to rule out developmental issues when considering a very early onset schizophrenia diagnosis. Symptoms in older children and teens include: social withdrawal sleep disruptions impaired school performance irritability irregular behavior substance use Younger individuals are less likely to have delusions, but they're more likely to have hallucinations. As teens get older, more typical symptoms of schizophrenia — like those seen in adults — usually emerge. It's important to have a knowledgeable professional make a diagnosis of childhood schizophrenia because it's so rare. It's crucial to rule out any other condition, including substance use or an organic medical issue. A child psychiatrist with experience in childhood schizophrenia should lead the treatment team and discussions about its plan. Treatment typically involves a combination approach that can include: Conditions related to schizophrenia Schizoaffective disorder Schizoaffective disorder is a separate and different condition from schizophrenia, but sometimes it gets lumped in with it. This disorder has elements of both schizophrenia and mood disorders. Psychosis, which involves a loss of connection with reality, is often a component. Mood disorders can include either mania or depression. Schizoaffective disorder is further classified into subtypes based on whether a person has only depressive episodes or whether they also have manic episodes with or without depression. Symptoms can include: paranoid thoughts delusions or hallucinations trouble concentrating depression hyperactivity or mania limited attentiveness to personal hygiene appetite disturbance sleep disruptions social withdrawal disorganized thinking or behavior Diagnosis is typically made through a thorough physical exam, interview, and psychiatric evaluation. It's important to rule out any medical conditions or any other mental illnesses like bipolar disorder. Treatments include: medications group or individual therapy practical life skills training Other related conditions Other related conditions to schizophrenia include: delusional disorder brief psychotic disorder schizophreniform disorder
Yahoo
6 hours ago
- Yahoo
Tampa Police get 300 new lifesaving choking devices from New York-based company
The Brief A company based in New York donated choking rescue devices to the Tampa Police Department. The devices, which are called LifeVac, create a one-way suction to remove lodged food or objects from a choking victim. These devices will be distributed to officers soon. TAMPA, Fla. - A New York-based company donated 300 choking rescue devices to the Tampa Police Department. These devices, called LifeVac, create a one-way suction to remove lodged food or objects from a choking victim. "This is just another tool for us, especially for our youth, to be out there and provide another opportunity to save a life," Tampa Police Chief Lee Bercaw said of the donation. The backstory Last month,a Tampa police officer used back blows to help save a toddler who was choking on a tomato. "That's the reason that we're getting this donation," Bercaw said Friday of the bodycam video. "[LifeVac inventor] Mr. Lih saw that video and said, 'I've got to get that product down here in a generous donation.'" "I knew as a parent, I'd be freaking out. I would be very distressed. So I tried to come up with something really simple. You push it, pull it, and that suction pulls it out," LifeVac President and Creator Arthur Lih said. These devices will be distributed to officers soon. Bercaw told FOX 13 the devices will be placed in patrol cars and will be used in schools and at Police Athletic League youth activities. Dig deeper As shown in LifeVac's online instructional video, the New York-based company said people should first follow choking protocols established by the American Red Cross. That means doing back blows and abdominal thrusts first. And if those actions don't work – or if those actions cannot be completed for whatever reason – then a LifeVac device can come into play. The U.S. Food and Drug Administration (FDA) encourages people to follow established choking rescue protocols by the American Red Cross and the American Heart Association. In an April 2024 update, the FDA said these protocols do not include anti-choking devices: "The safety and effectiveness of anti-choking devices that are being sold over-the-counter have not been established; they are not FDA approved or cleared." Success Stories Just this week, a Georgia police officer used a LifeVac device to save a driver choking on a water bottle cap. Years ago, LifeVac devices were placed in every school in Sarasota County. The Source The information in this story was gathered by FOX 13's Ariel Plasencia.
